System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Kohei Shitara is an expert in Oncology at National Cancer Center Hospital East (Japan). As of October 2026, ScienceLeadR ranks Kohei Shitara in the top 1% of experts worldwide for Stomach Neoplasms, Gastrointestinal Neoplasms and Carcinoma. Kohei Shitara has authored 838 publications, the most recent in 2026, and is an investigator in 43 clinical trials, 6 of them ongoing. SLR score: 4,696 (community average: 125). How the SLR is computed.

LeadR Profile

Kohei Shitara National Cancer Center Hospital East Japan
4 696 ScienceLeadR Reputation 4696

Unlock

Register Login
Network Map

Oncology

Subspecialties: Biochemistry - Pharmacy - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026
Source: PubMed

National Cancer Center Hospital (Japan, Tokyo)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 838

Citations

Citations: 31 698 1st author: 184 Last author: 168 Unique author: 11

Main journals

J Clin Oncol 187
Ann Oncol 149
Gastric Cancer 44
Cancer Res 27
Gan To Kagaku Ryoho 25

Best Journals

J Clin Oncol 119
Ann Oncol 79
Lancet Oncol 10

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Selection and Management of Patients With Resectable Gastric or Gastroesophageal Junction Cancer Receiving Perioperative FLOT: A Modified Delphi Consensus Approach.
PMID 42900867 — esophagogastric junction, neoplasms, fluorouracil		JCO Oncol Pract20260
Incidence, Clinical Characteristics, Management, and Outcomes of Hematologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Single-Center Japanese Retrospective Cohort Study.
PMID 42839531 — treatment outcome, incidence, neoplasms, cohort studies, immunosuppressive agents, drug therapy, heme, drug-related side effects and adverse reactions, immune checkpoint inhibitors, therapeutics, chemotherapy		Cancer Med20260
Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial.
PMID 42786305 — safety, paclitaxel, esophagogastric junction, neoplasms, biopsy, stomach neoplasms, trastuzumab		Nat Med Top journal20260
TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes.
PMID 42787785 — antigens, surface, esophagogastric junction, neoplasms, adenocarcinoma, drug therapy, biomarkers, therapeutics, stomach neoplasms, chemotherapy		ESMO Gastrointest Oncol20260
Early-onset chemotherapy-induced neutropenia and ascites control in patients with severe peritoneal metastasis of gastric cancer: a post hoc analysis of the JCOG1108/WJOG7312G trial.
PMID 42766838 — neutropenia, neoplasms, drug therapy, neoplasm metastasis, therapeutics, stomach neoplasms, ascites, chemotherapy		Jpn J Clin Oncol20260

Clinical Studies 43

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Chair: 1

By phase:

Phase 3 17
Phase 2 10
Phase 1 9
Phase 1/Phase 2 3
Phase 2/Phase 3 3
N/A 1

By status:

Completed 29
Active not recruiting 9
Recruiting 2
Unknown 2
Terminated 1

By type:

Interventional 43

By Monocentric/Multicentric:

monocentric 15
multicentric2to4 3
multicentric5to9 0
multicentricup10 25

Main Topics

Ongoing Clinical Trials

6 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
NCT07018570 — leucovorin, radiotherapy, docetaxel, esophagogastric junction, adenocarcinoma, drug therapy, oxaliplatin, fluorouracil, neoadjuvant therapy, therapeutics, infusions, intravenous, levoleucovorin, chemotherapy, carcinoma		Phase 2Recruiting2025
Beamion BCGC 1 A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2 Cancer That Has Spread
NCT06324357 — breast neoplasms, esophagus, esophagogastric junction, neoplasms, adenocarcinoma, maytansine, ado-trastuzumab emtansine, breast, therapeutics, colorectal neoplasms, capecitabine, trastuzumab		Phase 1/Phase 2Recruiting2024
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2 positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147 — cells, lewy bodies, stomach, parkinson disease, esophagus, neoplasms, adenocarcinoma, drug therapy, oxaliplatin, fluorouracil, immunotherapy, receptors, death domain, esophageal neoplasms, capecitabine, cell death, stomach neoplasms, trastuzumab, chemotherapy		Phase 3Active not recruiting2021
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
NCT05034887 — safety, pharmaceutical preparations, esophagogastric junction, neoplasms, adenocarcinoma, drug therapy, chemotherapy, adjuvant, neoadjuvant therapy, therapeutics, capecitabine, infusions, intravenous, stomach neoplasms, trastuzumab, chemotherapy		Phase 2Active not recruiting2022
A Study of Evorpacept (ALX148) in Patients With Advanced HER2 Gastric Cancer (ASPEN 06)
NCT05002127 — stomach, paclitaxel, esophagogastric junction, neoplasms, adenocarcinoma, esophageal neoplasms, stomach neoplasms, trastuzumab		Phase 2/Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS